Breaking news

Ozempic Approved By FDA For Chronic Kidney Disease Treatment

by THEFUTURE.TEAM

January 29, 2025

The U.S. Food and Drug Administration (FDA) has approved Ozempic for the treatment of patients with chronic kidney disease, marking a new milestone for Novo Nordisk’s highly popular drug, previously authorized for type 2 diabetes and weight loss.

Key Facts

The FDA approval allows Ozempic to be used to reduce the risk of kidney disease progression, kidney failure, and death from cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
The approval is based on a late-stage trial involving more than 3,500 participants, which showed that Ozempic lowered the risk of kidney disease progression and death from kidney or cardiovascular complications by 24% compared to a placebo.
Patients using Ozempic also experienced slower rates of kidney decline, according to Novo Nordisk.

In December 2024, the European Union’s health regulators also gave the go-ahead for Novo Nordisk to expand Ozempic’s label, indicating that the drug could reduce the risk of chronic kidney disease-related events in adults with type 2 diabetes.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Surprising Fact

The Centers for Disease Control and Prevention (CDC) estimates that one in every three adults with diabetes suffers from chronic kidney disease. Diabetes, both type 1 and type 2, can impair kidney function due to its effects on the kidneys’ ability to filter waste, compounded by the high blood pressure that often accompanies the condition.

What Has Ozempic Been Approved For?

Ozempic has already been approved by the FDA for type 2 diabetes management, and it’s also widely used off-label for weight loss. Additionally, the FDA authorized Novo Nordisk’s Wegovy—which contains the same active ingredient, semaglutide—for weight loss and lowering the risk of cardiovascular events, such as heart attacks and strokes.

Key Background

Ozempic and Wegovy are part of the GLP-1 agonist class of medications, which mimic the function of a gut hormone responsible for regulating blood sugar and appetite. Research into the broader benefits of these drugs has been growing. For example, Eli Lilly’s Zepbound, a competitor, was recently approved for treating obesity and sleep apnea, after it was shown to significantly reduce apnea events in a clinical trial.

Other studies suggest GLP-1 drugs might also have potential applications in treating alcohol use disorder and improving mood, cognitive function, and symptoms in patients with conditions like Parkinson’s, Alzheimer’s, dementia, bipolar disorder, and anxiety.

The Future Forbes Realty Global Properties

Cyprus Hotels Report Improved Bookings Ahead Of Summer Season

Overview of Booking Trends

The Chairman of the Pan-Cypriot Hotel Association, Thanos Michailidis, stated that there is a gradual improvement in booking activity. However, he cautioned that the current flow remains below expectations for May, with a similar outlook anticipated for June.

Seasonal Performance Concerns

According to Michailidis, booking activity has improved compared with March, but volumes remain lower than typically expected at this stage of the season. The shortfall has been particularly noticeable for July and August bookings, a trend that first emerged in March. At the same time, increased last-minute demand has provided some encouragement, with industry stakeholders closely monitoring booking patterns ahead of the peak summer season.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Implications Of The Israeli Market

Michailidis highlighted the growing importance of the Israeli market for Cyprus tourism. He noted that demand from Israeli travellers tends to respond quickly to changing conditions, making the market an important factor in the sector’s short-term performance.

The Critical Role Of Human Capital

Michailidis also pointed to staffing challenges facing the tourism industry. Regional instability in the Middle East has added uncertainty for employers seeking to retain and recruit personnel. He said government measures introduced in April helped address requests from the sector and supported efforts to maintain staffing levels during the summer period.

Competitive Pricing And Market Adaptations

Hotel operators continue to offer competitive pricing, according to Michailidis. Many businesses have expanded discounts for travel agents and introduced special offers targeting the domestic market in an effort to stimulate demand. He also noted that Cyprus faces structural challenges linked to air connectivity, with flight costs often remaining higher than those of competing destinations.

Key Markets And Future Prospects

The United Kingdom, Israel, Poland, Germany and the Scandinavian countries remain among Cyprus’ most important tourism markets, according to Michailidis. Domestic tourism also continues to play a significant role, particularly during holiday periods such as the Pentecost weekend.

Industry stakeholders are expected to monitor booking trends closely over the coming weeks as they assess demand for the remainder of the summer season.